Related Experiment Videos
Treatment of infantile spasms with sodium dipropylacetic acid
Insights
Sodium dipropylacetate shows promise for infantile spasms, with significant short-term responses. While long-term outcomes include developmental delays, it offers a potentially safer alternative to hormonal treatments for initial therapy.
Area of Science:
- Pediatric Neurology
- Clinical Pharmacology
- Developmental Neuroscience
Background:
- Infantile spasms are a severe epilepsy syndrome in infants.
- Current treatments like adrenocorticotropic hormone (ACTH) have significant side effects.
- Sodium dipropylacetate (Depakote) is an established antiepileptic drug.
Purpose of the Study:
- To evaluate the efficacy and safety of sodium dipropylacetate in treating infantile spasms.
- To compare outcomes with traditional hormonal therapies.
Main Methods:
- Eighteen infants diagnosed with infantile spasms received sodium dipropylacetate at 20mg/kg/day.
- Clinical assessments were performed before treatment and after one to three years of follow-up.
- Short-term clinical response and long-term outcomes including seizure control and cognitive status were evaluated.
Main Results:
- Short-term, 12 out of 18 infants showed a good or excellent clinical response.
- At follow-up, 2 infants were seizure-free, but 16 experienced significant cognitive impairment (moderate to severe mental retardation).
- Seven patients continued to have residual seizures, indicating incomplete long-term seizure control.
Conclusions:
- Sodium dipropylacetate demonstrates short-term efficacy in infantile spasms.
- Long-term outcomes suggest potential for developmental delays and persistent seizures.
- The authors propose sodium dipropylacetate as a first-line treatment due to fewer/milder side effects than ACTH, reserving hormonal therapy for non-responders.
Abstract:
Eighteen infants with infantile spasms were given sodium dipropylacetate at a dosage of 20mg/kg/day. They were clinically examined before treatment, and again after one to three years of therapy. The short-term clinical response was excellent in four patients, good in eight, poor in four and there was no change in two. At follow-up, two patients were clinically normal, but 10 had severe and six had moderate mental retardation. Seven patients still had residual seizures. Since these results do not differ significantly from those obtained with hormonal treatment, the authors suggest using sodium dipropylacetate (which has less frequent and less severe side-effects than adreno-corticotropic hormone) as the only initial drug, and to use hormonal treatment only in unresponsive patients.